Eye Drug Lucentis Recommended by UK’s NICE to Treat Wet AMD
Novartis AG's Lucentis drug against wet age-related macular degeneration (AMD) received a recommendation from the UK's National Institute for Health and Clinical Excellence (NICE) for use on the National Health Service.
Lucentis should be used for about 20 pct of patients with AMD, a condition which causes sight loss and blindness, when both eyes are affected, NICE said in a statement last night.
NICE said it does not recommend the use of OSI Pharmaceuticals Inc (nasdaq: OSIP - news - people )'s rival eye treatment Macugen.
Filed under Eye Treatment, Macular Degeneration
You may also like to read
- Most expensive drug "Lucentis" now available through cost effective scheme by NICE
- Lucentis - Wet Macular Degeneration Drug is Highly Successful in Clinical Trials
- Brand New Treatment For Macular Degeneration
- Hope for Age Related Macular Degeneration with Lucentis
- Macular Degeneration and its New Treatments
- Single Mass Antibiotic Treatment Is Not Enough To Treat And Eliminate Trachoma
- Midwest Eye Institute Doctor Helps To Test Drug For Macular Degeneration
- Novagali eye Treatment for Vernal Keratoconjunctivitis (VKC) Successful in Phase III Trial
- Food and Drug Administration Panel Rejects 'Bionic Eye' for Citing Safety
- STAAR Seeks FDA Approval of Visian TICL Implantable Contact Lens For Nearsightedness and Astigmatism Treatment
August 22nd, 2007 at 9:41 am
I just wanted to make everyone aware of a recent press release, “Doctors Say Start Sweating To Improve Vision” from VisiVite.com. The release noted that a study on wet macular degeneration has been published in the British Journal of Ophthalmology. The study suggested that wet AMD sufferers who exercised several times a week reduced their possibility of contracting wet AMD by up to 70%. Also, based on the results of the recent AREDS study, VisiVite.com has found that Macular Degeneration Vitamins may also reduce the chance of contracting age related macular degeneration.
April 13th, 2008 at 7:29 pm
This drug has also been recommended for approval now in Canada. The Common Drug Review committee (CDR) has recommended to provincial health care departments that this drug should be included in their drug programs.